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Abstract
Background: There have been few prospective observational studies which recruited older
newly-diagnosed cancer patients, and of these only some have reported information on the number
needed to screen to recruit their study sample, and the number and reasons for refusal and drop-
out. This paper reports on strategies to recruit older newly-diagnosed cancer patients prior to
treatment into an observational prospective pilot study and to retain them during a six-month
period.
Methods: Medical charts of all patients in the Segal Cancer Centre aged 65 and over were
screened and evaluated for inclusion. Several strategies to facilitate recruitment and retention were
implemented. Reasons for exclusion, refusal and loss to follow-up were recorded. Descriptive
statistics were used to report the reasons for refusal and loss to follow-up. A non-response analysis
using chi-square tests and t-tests was conducted to compare respondents to those who refused to
participate and to compare those who completed the study to those who were lost to follow-up.
A feedback form with open-ended questions was administered following the last interview to
obtain patient's opinions on the length of the interviews and conduct of this pilot study.
Results: 3060 medical charts were screened and 156 eligible patients were identified. Of these 112
patients participated for a response rate of 72%. Reasons for refusal were: feeling too anxious
(40%), not interested (25%), no time (12.5%), too sick (5%) or too healthy (5%) or other reasons
(5%). Ninety-one patients participated in the six-month follow-up (retention 81.3%), seven patients
refused follow-up (6.2%) and fourteen patients died (12.5%) during the course of the study. The
median time to conduct the baseline interview was 45 minutes and 57% of baseline interviews were
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conducted at home. Most patients enjoyed participation and only five felt that the interviews were
too long.
Conclusion:  It was feasible to recruit newly-diagnosed cancer patients prior to treatment
although it required considerable time and effort. Once patients were included, the retention rate
was high despite the fact that most were undergoing active cancer treatment.
Background
Cancer is a common health problem for older persons.
Nevertheless, the manifestations and course of cancer in
this older population have not been well investigated and
remain poorly understood [1-6]. Moreover, with the aging
of the population both the absolute and the relative
number of older patients affected by cancer can be
expected to increase in the future [7,8]. There is increasing
interest in conducting research on health and functional
status in older cancer patients [9,10]. It has been suggested
that frailty might be a useful concept to identify vulnera-
ble older patients at risk of adverse outcomes of treatment
who then might benefit from comprehensive geriatric
assessment [11,12]. Frailty represents a state of reduced
homeostasis and resistance to stress, due in part to aging,
which leads, in turn, to increased vulnerability and risk of
adverse outcomes although there is no consensus on the
definition. Fried et al [13] have developed a now com-
monly used approach to measure frailty. The five charac-
teristics of their frailty phenotype are: weakness, poor
endurance, reduced physical activity, slow walking speed,
and unintentional weight loss during the preceding year.
Cognitive impairment and depressed mood have recently
been added [14,15]. Unlike their non-frail contemporar-
ies, frail older individuals appear unable to withstand
stressors, such as environmental stress, injury, and acute
illness. These stressors may provoke a downward spiral,
whereby the frail older individual is unable to recover and
return to the baseline state [13,14,16]. In older patients,
cancer treatments, especially chemotherapy, are consid-
ered strong stressors that will reveal which patients have
sufficient functional reserve to regain stable homeostasis
[3,17]. To our knowledge, there has been no prospective
observational study investigating the usefulness of the
concept of frailty in the field of geriatric oncology.
There have been many studies that have reported that
older patients are underrepresented in cancer clinical tri-
als due to a variety of reasons [6,18-27]. Furthermore,
investigators have reported that recruiting older patients
to any clinical trial is difficult due to co morbidity, cogni-
tive problems, sensory deficits, transportation issues,
study burden and influence of significant others [28-35].
As observational studies do not bring personal advantage
or direct benefits for patients as do clinical trials, the rea-
sons for participation and refusal might be different than
for clinical trials. Newly-diagnosed cancer patients may
also be asked to participate in a cancer clinical trial at the
same time as being asked to participate in an observa-
tional study which may increase the burden on the older
patients and may affect response rates and retention rates
in both studies. Few observational studies have reported
information on the number needed to screen to recruit
the study sample, or the number and reasons for refusal
and drop-out [36,37]. Furthermore, most of the studies
have been cross-sectional with small sample sizes and/or
with only one type of cancer diagnosis included [38-42].
The studies with older cancer patients have defined their
older patients with no cut-off based on age [36,37], 65
years and over [39,41] or 70 years and over [38,40,42].
More information on recruitment and retention strategies
may facilitate or increase participation of older newly-
diagnosed cancer patients in studies on health and func-
tional status.
In the context of an observational prospective pilot-study
conducted to describe the health and vulnerability of
older newly-diagnosed cancer patients and the adverse
outcomes of treatment, we evaluated and report our
recruitment and retention strategies to optimize their use
for future larger studies. As we were interested whether the
concept of frailty is useful to identify older patients at risk
of adverse outcomes of cancer treatment, it was crucial to
conduct the baseline interview prior to cancer treatment.
The window of opportunity for recruitment of older
newly-diagnosed cancer patients was thus narrow, making
recruitment more challenging. The aim of this study was
to examine the feasibility of recruitment older newly-diag-
nosed cancer patients prior to treatment into an observa-
tional prospective pilot study and to retain them during a
six-month follow-up period.
Methods
Study population
The study sample was recruited at the Segal Cancer Centre
which is a comprehensive cancer centre. It is a referral
center for local and regional patients. It serves the adult
population referred by other doctors and other hospitals
in Quebec for further investigation and cancer treatment
[see Figure 1]. Each year more than 5,000 patients are seen
for a total of more than 70,000 visits per year. The Segal
Cancer Centre includes surgeons, medical oncologists,
haematologists, radiation oncologists and pulmonary
oncologists involved in patient's cancer treatments. TheBMC Cancer 2009, 9:277 http://www.biomedcentral.com/1471-2407/9/277
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inclusion criteria for this study were: patients referred to
the Segal Cancer Centre of the Jewish General Hospital,
McGill University, Montreal, Canada, aged 65 and older,
with a new diagnosis of solid tumour with or without
metastasis (i.e. breast, colorectal, or lung cancer) or hae-
matological malignancy (i.e. lymphoma and myeloma),
who had not received cancer treatment in the previous five
years. The only exception was for those who had started
hormonal therapy less than 1 month prior to the study.
These particular cancer diagnoses were chosen as they are
among the most common cancers diagnosed in older
Canadians [43]. The age cut-off was chosen since this cut-
off is often used in longitudinal aging studies and has
been used previously in studies with older cancer patients
[39,41]. Exclusion criteria were: unable to speak English
or French, estimated life expectancy less than 3 months,
unable to give informed consent because of cognitive
impairment. The study was approved by the Research Eth-
ics Committee of the Jewish General Hospital, McGill
University, Montreal, Canada. All participants gave writ-
ten informed consent.
Study description
The baseline interview took place prior to cancer treatment
and the participants were followed for six months with
face-to-face follow-up interviews at three and six months
and telephone interviews at 1.5 and 4.5 months [see Addi-
tional file 1]. The baseline interview consisted of ques-
tions on sociodemographics, health (lifestyle factors) and
functional status, comorbid conditions, use of medica-
tions, disability in instrumental and daily living, quality
of life, anxiety and depression, and use of health care [44-
51]. In addition, to evaluate the frailty markers, nutrition
(including weight and height), grip strength and gait
speed were assessed and cognitive functioning tests were
administrated [52-56]. The third and fifth face-to-face fol-
low-up interviews included the same questions with the
exception of the sociodemographic data which was only
included in the baseline interview. The second and fourth
interview which was conducted by telephone included
health and functional status, disability in daily and instru-
mental activities of daily living, quality of life and the use
of health care.
Recruitment strategies
Patients were identified through the lists of appointments
at the oncology, pulmonary oncology and haematology
oncology clinics. A letter to the physician including the
inclusion and exclusion criteria and a patient information
letter were added to the chart of each eligible patient (see
Table 1 with recruitment strategies by diagnosis). If the
patient was found to be eligible, the treating physician
then asked the patient if he/she could be contacted by tel-
ephone or be seen after the consultation by a member of
the research team to explain the study and discuss poten-
tial participation. A member of the research team invited
the patient to participate and when they agreed, an inter-
view date was set with the patient choosing to do the inter-
view at home or at the hospital. The Department of
colorectal surgery is located outside the Segal Cancer Cen-
tre and for logistical reasons it was not possible to identify
potential eligible patients through the lists of appoint-
ments. The surgeons of patients newly-diagnosed with
colorectal cancer identified eligible patients and asked
them if they could be contacted by the research team.
These patients were seen by a member of the research
team at the inpatient ward the day they were admitted for
their surgery planned for the following day. If they agreed
to participate the interview was done the day of admis-
sion. Screening of the medical charts, contacting the par-
ticipants and the interviews were done by MP (trained as
a nurse), VG (medical oncologist) and MM (trained as an
occupational therapist). MP and VG started recruitment
and interviews and MM assisted with the conduct of inter-
views. Recruitment began on March 1st 2007 and ended
on January 31st 2008 for all cancers except colorectal can-
cer for which recruitment ended on May 1st 2008.
Retention strategies
A combination of retention strategies was used. Partici-
pants were offered home visits or transportation to the
Flow chart of patients in the Segal Cancer Centre and the  recruitment Figure 1
Flow chart of patients in the Segal Cancer Centre 
and the recruitment.
Letter for doctor in the chart 
with the aim of the study 
and eligibility criteria and 
the patient information 
letter
The oncologist/ hematologist/ 
surgeon sees the patient and plans 
further investigation/ plans first 
treatment / refers to another 
specialist 
Patient is booked for first treatment 
on the treatment floor and often the 
patient meet the nurse assigned to 
him/her during treatment /patient is 
booked for surgery 
If patient is eligible, the 
doctor asks if the patient 
can be contacted by the 
research team to explain 
the study and doctor gives 
the patient information 
letter
Patient comes back for 
treatment/surgery
Secretary keeps a list of 
new patients and their 
first appointment
Patients contact the secretary to 
make the first appointment
Persons with a referral of a GP/ 
other specialist to the outpatient 
clinic of the Segal Cancer Centre 
Patient is contacted by a 
member of the research 
team, and if the patient 
agrees to participate a 
date and time for the first 
interview is set  BMC Cancer 2009, 9:277 http://www.biomedcentral.com/1471-2407/9/277
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hospital and they were interviewed at their preferred time.
Participants were offered transportation/compensation of
costs for a hospital visit if they had no other appointment
that day. Furthermore, they were offered the opportunity
to complete the face-to-face interviews in two parts if it
was not possible for them, for whatever, reason to com-
plete it in one interview.
As far as possible participants were interviewed by the
same person and all participants were sent holiday cards
while on study. Patients were also give fridge magnets
with the telephone numbers how to reach the study team.
Prior to each telephone interview the patient was sent a
letter reminding them of the date and time of the inter-
view. Also the questionnaire was sent with this letter to
facilitate the interview. For participants with visual or
hearing impairment the patients were asked what they
would prefer: a face-to-face interview or to receive the
questionnaire with a pre-stamped return envelope to
complete themselves instead of the telephone interview.
Lastly, during the informed consent procedure, partici-
pants were asked permission to contact a proxy in case the
research team could not contact them during the follow-
up period or they would not feel well enough to do the
interview.
Data collection
The medical charts of all patients in the Segal Cancer Cen-
tre aged 65 and over were screened and evaluated for
inclusion. The reasons for exclusion were recorded for
potentially eligible patients (i.e. a new diagnosis of can-
cer). Furthermore, the reasons for refusing to participate
by eligible patients, the reasons for drop-out, the number
of meetings and time required to complete the interview
and reasons for postponement were recorded. The time
needed to complete the interview was defined as the time
between the start and the end time of the interview. If the
interview was completed in two parts the total time was
summed. The time needed to complete the interviews was
only calculated for those respondents who completed the
entire interview, i.e. those who completed all of the differ-
ent measurements and questionnaires and who had a
time available. Interviews that were not entirely com-
pleted are referred to as incomplete interviews throughout
the article. Postponement was recorded when the
respondent did not want to schedule the interview or do
the planned interview when he or she was contacted. In
these cases the reason for postponement was asked. The
number of days necessary to complete the entire study was
calculated for the participants who participated in all five
interviews.
To compare the baseline characteristics of those who com-
pleted the study, died while on study or refused further
follow-up we used the baseline sociodemographic infor-
mation collected (age, sex, marital status, living situation
(grouped as alone or not alone), and born in Canada (yes
or no)). Information on diagnosis, stage of disease, treat-
ment plan proposed and whether or not they were
enrolled in a clinical trial was obtained from the medical
records. The extent of disease at diagnosis was classified as
early (stage 0–2) or advanced (stage 3–4). The Eastern
Oncology Cooperative Group Performance Scale (ECOG
PS) (grouped as 0, 1 and ≥ 2) [49] was used to classify
functional status. Anxiety and depression were assessed
using the Hospital Anxiety and Depression Scale (HADS;
a score >10 as possible impairment) [50], cognition using
the Mini Mental State Examination [52] and the Montreal
Cognitive Assessment Tool (MoCa) (a score of 26 or
below on either MMSE or MoCa indicating cognitive
impairment) [53], Instrumental activities of daily living
(IADL disability, used as no IADL disability or ≥ 1 IADL
disability) was measured using the Older American
Table 1: Overview of Recruitment Strategies by Cancer Diagnosis
Strategy used Lung cancer Breast cancer Lymphoma/Multiple myeloma Colorectal cancer
Screening charts for clinics in Segal Cancer 
Centre
XX X X
Attending tumor board X X X X
Letter for MD with inclusion and exclusion 
criteria in chart and patient info letter in 
chart of potential patient
XX X X  
(in Segal Cancer Centre, not in the 
Department of colorectal surgery)
After consultation contact MD to verify 
eligibility and to ask the MD if the patient 
agreed to be contacted
XX X X
Contact the secretary of each of the 
departments each week to see list of new 
patients
XX X
Contact the surgeons to verify new eligible 
patient
X
Contact the nurse/MD to confirm eligibility 
and approached the patient the day before 
the surgery
XBMC Cancer 2009, 9:277 http://www.biomedcentral.com/1471-2407/9/277
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Resources and Services [46]. The Katz index was used for
disability in activities of daily living (ADL disability, used
as no ADL disability vs. ≥ 1 ADL disability) [47] and the
functional comorbidity index was used the calculate the
number of comorbid conditions [44].
Feedback from patients
Patients who completed the follow-up of 6 months were
asked to provide feedback by filling out a one-page ques-
tionnaire after the last interview. Participants were asked
to gauge the strength of their agreement with the state-
ment "I found the length of the interview too long"
(strongly disagree to strongly agree) for both the tele-
phone and face-to-face follow-up interview. Furthermore,
they were asked three questions: 1) Are there questions
that you found irrelevant, unpleasant or too difficult? If
yes, could you explain why? 2) Are there topics that we did
not discuss in this study, but you find important for your
health and functional status (meaning your ability to do
your normal daily activities)? 3) Other comments or sug-
gestions with regard to the conduct of this study?
Statistical analysis
Descriptive statistics including means and proportions
were used to describe the characteristics of those who were
newly-diagnosed but excluded because they did not fulfill
all inclusion criteria, of the patients who refused and of
the patients who participated in the study. A non-
response analysis was conducted using chi-square tests
and two-sample t-tests. Descriptive statistics were used to
describe the mean duration and the reasons for postpone-
ment of interviews and the opinion of patients on the
length of the interviews. To examine if the feasibility
(defined as number of days needed to complete the study,
duration of the interviews, number of postponed inter-
views and number of interviews completed in one or two
meetings or incomplete) of the study was different based
on the characteristics of the patients, the participants were
grouped in several ways. The participants were divided
into groups based on median age at baseline (74.1 years),
sex, living situation, born in Canada, diagnosis, extent of
disease, number of comorbid conditions, IADL disability,
and ADL disability. Descriptive techniques such as fre-
quencies and crosstabs were used to compare if the groups
based on the characteristics mentioned above differed
with regard to the feasibility of the study. The answers to
the open-ended feedback questions were transcribed,
grouped and counted. Statistical analyses were performed
using SPSS version 15.0 (SPSS Inc., Chicago, Illinois,
USA).
Results
From March 1st 2007 until May 1st, 2008, 3060 medical
charts of patients aged 65 and over were screened in the
Segal Cancer Centre; see Figure 2. Of those 3060 patients,
2838 were excluded (ineligible) because they were treated
for cancer in the past 5 years, they were being seen for fol-
low-up appointments after cancer treatment or the patient
was investigated for cancer but did not have cancer. There
were 222 newly-diagnosed patients to review for further
eligibility. Of those 222, 66 were excluded (see Figure 2
for the reasons) leaving 156 eligible patients. Of these,
116 patients agreed to participate. 114 signed informed
consent and two persons had to be excluded because they
received treatment before the planned interview took
place. Of the 114 patients who signed informed consent,
one patient died before the baseline interview. A second
patient completed the baseline interview but following a
second opinion the cancer diagnosis was changed to a
non-malignant diagnosis and the patient was excluded.
Finally, 112 participants completed the baseline interview
(72% of all eligible patients).
Of the 40 patients (25.6%) who refused to participate, 16
reported that they felt overwhelmed/sad by the diagnosis,
were too anxious in relation to the start of their cancer
treatment, 5 patients did not feel well enough to partici-
pate, 5 patients had no time (due to care giving responsi-
bilities, moving or work, or start of treatment next day), 2
patients felt too healthy, 10 persons were not interested, 1
patient refused due to study burden as the patient was also
enrolled in a clinical trial and the last person refused due
to denial of the cancer diagnosis. However, half of them
indicated that they would be willing to participate after
the start of treatment (i.e. knowing then what the treat-
ment would be like).
The baseline characteristics of those who participated,
those who refused to participate and those who were
excluded are presented in Table 2. The only statistically
significant difference between those who participated and
those who refused was that participants were less often
married/living common-law (p = 0.006).
The baseline characteristics of participants who com-
pleted the study, died during the study or refused further
follow-up interviews are presented in Table 3. Due to the
small number of patients who refused, statistical analyses
were not conducted comparing these groups. During the
study, 14 participants died (12.5%) before the last inter-
view and one patient died following completion of the
first half of the interview. As shown in Table 3, those who
died seemed to be in worse health and functional status at
the baseline interview compared to those who completed
the study or refused further follow-up.
Seven participants (6.3%) refused follow-up after the
baseline interview. There was an additional patient who
refused the third and fourth interview due to a lack of time
but participated in the final interview. The reasons forBMC Cancer 2009, 9:277 http://www.biomedcentral.com/1471-2407/9/277
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refusal were not longer interested (3), no time (1), too
overwhelmed by diagnosis and treatment (2), sick hus-
band (1).
Sixty four (57.1%) of all baseline interviews were con-
ducted at home and the remainder were conducted in the
hospital, see Table 4. During the course of the study, 61
interviews were postponed by 44 participants. The
median time needed to complete the baseline interview
(n = 87) was 45 minutes (Interquartile range (IQR) 40–
55), 10 minutes for the second interview (N = 77) (IQR 8–
15), 45 minutes for the third interview (N = 70) (IQR 35–
50), 10 minutes for the fourth interview (N = 70) (IQR
10–15) and 40 minutes for the fifth interview (N = 71)
(IQR 35–55). The results of the feasibility of the study
according to patients' characteristics showed only some
minor differences were observed with not one group for
whom participation was less feasible [see Additional file
2].
During the study, 2 participants became very ill and proxy
interviews were conducted (both participants had lung
cancer). For two other participants with cognitive impair-
ment a proxy respondent completed the telephone inter-
view while the face-to-face interviews were conducted
with the patient and the proxy together. Only two partici-
pants used the transportation offered to come to the hos-
pital for an interview. Nobody used the offer to be
compensated for transportation costs to the hospital.
In addition, patients were asked their opinion on partici-
pating in this study and 84 participants provided feedback
(see Table 5). Most did not identify specific questions that
they felt were unpleasant or too difficult but did mention
that nothing was unpleasant or too difficult. The majority
of patients indicated that in their opinion there was no
item or topic missing. A third of patients indicated that
they had enjoyed participating in this study.
Discussion and conclusion
Our results show that it was feasible to recruit newly diag-
nosed cancer patients prior to treatment although this did
require considerable time and effort. Although no infor-
mation was recorded systematically on the number of
hours necessary to recruit potential participants by mem-
bers of the research team, we estimate that on average it
took 3 hours to recruit the potential eligible subjects. This
estimate does not include the time needed to assess eligi-
bility. One member of the research team worked fulltime
on the recruitment and conduct of interviews. We found
it necessary to modify our strategies depending on cancer
type. It was more difficult to identify and recruit eligible
patients with colorectal cancer compared to the other can-
cer diagnoses for which the research team had access to
the clinic lists. For colorectal cancer the treating surgeon
had to alert us when they had a new patient. Regardless of
strategies implemented to remind physicians, we found
that it was important to be present in the clinics when
physicians see their patients to reinforce the reminder. We
found that at the time of recruitment it was important to
meet the patient in the physician's office so that the
patient would know who was going to call them to
explain the study. This finding is in keeping with the work
of others [28]. We also observed that patients wanted to
know the treatment plan before they could decide whether
or not to participate in this pilot study. During the
informed consent procedure a number of questions were
asked about the possibility of withdrawing from the
study. It was stressed many times that they could with-
draw at any time without providing a reason. Despite
these initial concerns, during the study this was not a
major issue as only two participants dropped out of the
study because of the burden of treatment. We also noticed
that some patients and family members had different
views about whether or not they should participate in the
study. In some cases, family members were concerned
about the study burden in combination with the cancer
treatment even when the patients wanted to participate.
When this arose, this concern was successfully addressed
by also giving family members all the study information
to help them understand the study. Interestingly, in a few
cases, patients refused to participate and subsequently
their family members asked if they could participate as a
proxy, a strategy not included in the study design.
It was important to actively recruit patients after they had
agreed to be contacted for the study as none of the
patients contacted the research team for information
about the study. This is in agreement with Townsley et al.
[27] who conducted a survey among elderly patients con-
cerning their willingness to participate in cancer clinical
trials and found that most elderly patients were willing to
consider participation but did not appear to actively seek
information about trials. Our overall recruitment was
72% of eligible patients in spite of the limited time win-
dow available to recruit patients. This rate is about the
same as reported in other studies with older cancer
patients. It is higher than another study with newly-diag-
nosed cancer patients with breast, colon, lung or colorec-
tal cancer who were recruited within 6 weeks of initial
surgery or within 2 weeks of initiating chemotherapy or
radiation therapy who reported a response rate of 51%
[36-38]. However, a high number of patients had to be
screened to recruit those patients. A review on attrition in
large longitudinal aging studies (>1000 participants)
around the world showed initial response rates of 63 toBMC Cancer 2009, 9:277 http://www.biomedcentral.com/1471-2407/9/277
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Overview Recruitment and retention in the study Figure 2
Overview Recruitment and retention in the study.
Excluded 2838:
Treated in the last 5 years, or follow-up 
222 newly-diagnosed patients   Excluded 66:
-Does not speak English or French 18  
-Life expectancy less than 3 months 14  
-Does not know cancer diagnosis 9 
-Unable to contact patient before the start of 
treatment 8 
-MD does not want this patient in the study for 
reasons of anxiety, many other medical problems 7 
-Cognitively not able to give informed consent 4 
-Being seen only for second opinion 3 
-Other reasons 3 
156 eligible patients (100%) 
40 refused to 
participate 
(25.6%)
116 (74.4%) agreed to 
participate in baseline 
interview 
2 (1.3%) agreed to participate, appointment for 
interview was made but received treatment before 
the planned interview 
101 participated (90.2% of 112) in 2nd interview by telephone 6 weeks after baseline:
6 died (5.4%), 5 refused (4.5%)
97 participated (86.6% of 112) in 3rd interview face-to-face 12 weeks after baseline: 
1 died (0.9%), 3 refused (2.7%)* 
94 participated (83.9% of 112) in 4th interview by telephone 18 weeks after baseline:
3 died (2.7%), 1 refused (0.9%)* 
114 (73.1%) signed informed consent  
112 (71.8%) participated with baseline 
interview 
2 patients were excluded (1.3%); 1 patient died 
before the interview and 1 patient participated in 
the interview but turned out not to have cancer
91 participated (81.3% of 112) in 5th interview face-to-face 24 weeks after baseline:
4 died (3.6%), 1 patient participated in part and then died while on study 
3060 patients aged 65 and over 
*=one person refused to participate in third and fourth interview but did participate in interview 5.BMC Cancer 2009, 9:277 http://www.biomedcentral.com/1471-2407/9/277
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93% [57]. Our response rate compares very favourably
considering that this is a population of newly-diagnosed
cancer patients recruited before the start of treatment.
We compared the participants on several characteristics to
identify potential differences in the feasibility of recruit-
ment and retention in this pilot study. There were only
minor differences observed. It seemed that those with a
poorer functional status needed more time to complete
the interviews, the study overall and required more meet-
ings to complete an interview. Similar findings were
reported by Pijls-Johannesma et al[58] in a study compar-
ing different quality of life instruments. They found that
patients with lung cancer who all had a poor performance
status, needed assistance more often to complete the
assessment tool than patients with breast cancer. In addi-
tion, we found that patients born outside Canada,
required more effort to complete an interview and more
often had an incomplete interview. Patients were included
in the study if they could understand and speak English or
French and the study material was provided in English
and French. However, some of the foreign-born partici-
pants found the questionnaires were too difficult and this
may have led to the higher number of incomplete inter-
views. The cognition tests and the HADS were most often
missing for foreign-born patients. In the 2006 census
http://www.statcan.ca, 19.5% of Canada's population was
born outside Canada. For future studies it is important to
pay attention to the feasibility of study design and meas-
urement tools of foreign-born older adults.
We noted that once enrolled in the study, the retention
rate was high (81%) despite the fact that the majority of
participants were undergoing active cancer treatment.
Most patients did not feel that the interviews were too
long. From the feedback received from patients, most had
enjoyed participating in the study. In the few prospective
studies published with older cancer patients, the attrition
rate ranged from 2% to 37%, in part due to study differ-
ences in baseline age and disease status, treatment regimes
and length of follow-up time (ranging between 6 months
to 1 year follow-up) [38,40,41,59-61]. The review on attri-
tion in large longitudinal aging studies [57] showed that
attrition was associated with increasing age and those who
Table 2: Characteristics of Participants, those who Refused or were Excluded
Characteristic Participated
N = 112 (%)
Refused to participate N = 40 (%) Excluded
N = 70 (%)
Mean age at screening (SD) 73.7 year (6.0) 74.4 year (5.8) 76.2 year (6.6)
Sex (%)
Female 78 (69.6) 21 (52.5) 39 (55.7)
Male 34 (30.4) 19 (47.5) 31 (44.3)
Language of the patient (%)
French 41 (36.6) 8 (20.0) 12 (17.1)
English 71 (63.4) 32 (80.0) 22 (31.4)
Neither 0 0 21 (30.0)
No information 0 0 15 (21.4)
Marital status (%)
Married/living common-law 62 (55.4) 31 (77.5) 45 (64.3)
Widowed 25 (22.3) 7 (17.5) 12 (17.1)
Separated/divorced 19 (17.0) 0 2 (2.9)
Single 6 (5.4) 0 6 (8.6)
No Information 0 2 (5.0) 5 (7.1)
Type of cancer (%)
Lung 27 (24.1) 17 (42.5) 28 (40.0)
Breast 44 (39.3) 11 (27.5) 21 (30.0)
Colorectal 20 (17.9) 7 (17.5) 11 (15.7)
Lymphoma & myeloma 21 (18.8) 5 (12.5) 10 (14.3)
Treatment proposed (%)
Watchful waiting 2 (1.8) 1 (2.5) 11 (15.7)
Surgery 54 (48.2) 19 (47.5) 28 (40.0)
Chemotherapy 42 (37.5) 15 (37.5) 14 (20.0)
Radiation therapy 10 (8.9) 4 (10.0) 9 (12.9)
Hormonal therapy 4 (3.6) 1 (2.5) 4 (5.7)
Other 0 0 4 (5.7)
Cancer diagnosis (%)
First diagnosis 100 (89.3) 34 (85.0) 62 (88.6)
Recurrence 2 (1.8) 4 (10.0) 6 (8.6)
New diagnosis, not first cancer diagnosis 10 (8.9) 2 (5.0) 2 (2.9)BMC Cancer 2009, 9:277 http://www.biomedcentral.com/1471-2407/9/277
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are in worse health. In our study, attrition due to refusal
was highest among patients with colorectal cancer which
might be due to the fact circumstances and different
method of recruitment and attrition due to death was
highest amongst patients with lung cancer. These findings
are in agreement with the study of Neumark et al. who
found that dropout was highest among patients with
colorectal and lung cancer [37]. At a University teaching
hospital newly-diagnosed cancer patients may also be
asked to participate in a cancer clinical trial at the same
Table 3: Overview of those who Completed, Refused or Died during the Study
Characteristic Completed the study
N = 90 (%)
Died during study
N = 15 (%)
Refused follow-up
N = 7 (%)
Mean age at baseline interview (SD) 73.6 year
SD (6.2)
72.9 year
SD (4.6)
76.7 year
SD (6.0)
Sex
Female 66 9 6
Male 24 6 1
Marital status
Married or living common-law 46 12 4
Widowed 22 2 1
Separated/divorced 18 0 1
Single 41 1
No Information 0 0 0
Lives alone
Yes 37 5 3
No 53 10 4
Born in Canada
Yes 50 11 4
No 40 4 3
Type of cancer/alive at end of study and completed study
Lung 19/19 (100%) 8 0
Breast 41/44 (93.2%) 0 3
Colorectal 14/18 (77.8%) 24 4
Lymphoma 13/13 (100%) 1 0
Multiple myeloma3 / 3  ( 1 0 0 % ) 0 0
Extent of disease at diagnosis
Early (stage 0–2) 55 2 6
Advanced (stage 3–4) 35 13 1
Enrolled into clinical trial
Yes 71 4 7
No 83 1 0
Treatment proposed
Watchful waiting 2 0 0
Surgery 47 1 6
Chemotherapy 29 13 0
91 0
Radiation therapy
Hormonal therapy
30 1
Cancer diagnosis
First diagnosis 79 14 7
Recurrence 2 0 0
New diagnosis, not first diag. 9 1 0
Ecog Performance scale at baseline
0 65 (72.2) 2 (13.3) 5 (71.4)
1 14 (15.6) 6 (40.0) 2 (28.6)
2 9 (10.0) 3 (20.0) 0
3 2 (2.2) 4 (26.7) 0
4. 00 0
Mood impairment (HADS A or D ≥ 10) 18 (20.0) 7 (46.7) 1 (14.3)
Cognitive impairment (MMSE ≤ 26 or Moca ≤ 26) 3 (3.3) 3 (20.0) 2 (28.6)
IADL disability (OARS) 27 (30.0) 8 (53.3) 4 (57.1)
ADL disability (Katz) 7 (7.8) 4 (26.7) 1 (14.3)
Mean number of self-reported comorbid conditions 
(Functional comorbidity Index)
2.0 (SD 1.9) 3.3 (SD 2.5) 1.9 (SD 1.2)BMC Cancer 2009, 9:277 http://www.biomedcentral.com/1471-2407/9/277
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Table 4: Location of Interview and Number of Interviews Needed to Complete the Questionnaire
Interview 1 Baseline Face-to-face N = 112 Number of interviews
Face-to face interview at home 64 (57.1%)
Face-to-face interview at the hospital 48 (42.9%)
Complete interview and interview time available 87 (77.7%)
Interview 2 Telephone interview after 6 weeks N = 101
Interview by telephone 65 (64.4%)
In hospital face-to-face interview 14 (13.9%)
Returned self-administrated questionnaire by mail 9 (8.9%)
Returned self-administrated questionnaire in hospital 13 (12.9%)
Number of Interviews 2 postponed and reason 16 (100%)
Not feeling well 5 (31.3%)
Postponed to combine with next hospital visit 2 (12.5%)
Away for holiday 1 (6.3%)
Admitted to hospital 3 (18.8%)
Had not received questionnaire by mail 3 (18.8%)
For other reasons (too busy) 2 (12.5%)
Interview 3 Face-to-face interview after 12 weeks N = 97
Face-to face interview at home 45 (46.4%)
Face-to-face interview at the hospital 45 (46.4%)
Filled out questionnaire at home and measurements in hospital 6 (6.2%)
Returned self-administrated questionnaire by mail* 1 (1.0%)
Complete interview and interview time available 78 (80.4%)
Number of Interviews 3 postponed and reason 14 (100%)
Not feeling well 4 (28.6%)
Postponed to combine with next hospital visit 3 (21.4%)
Away for holiday 3 (21.4%)
Admitted to hospital 1 (7.1%)
For other reasons (too busy) 3 (21.4%)
Interview 4 telephone interview after 18 weeks N = 94
Interview by telephone 56 (59.6%)
In hospital face-to-face interview 14 (14.9%)
Returned questionnaire by mail* 8 (8.5%)
Returned questionnaire in clinic 16 (17.0%)
Number of Interviews 4 postponed and reason 10 (100%)
Not feeling well 4 (40.0%)
Illness/death family or friends 1 (10.0%)
Postponed to combine with next hospital visit 1 (10.0%)
Admitted to hospital 2 (20.0%)
Had not received questionnaire by mail 2 (20.0)
Interview 5 Face-to-face interview after 24 weeks N = 91
Face-to face interview at home 46 (50.5%)
Face-to-face interview at the hospital 35 (36.1%)
Face-to-face interview in Rehab center 1 (1.1%)
Returned self-administrated questionnaire by mail* 1 (1.1%)
Filled out questionnaire at home, measurements in clinic 8 (8.8%)
Complete interview and interview time available 71 (78.0%)
Number of Interviews postponed and reason 21 (23.1%)
Not feeling well 4 (19.0%)
Illness/death family or friends 3 (14.3%)
Postponed to combine with next hospital visit 5 (23.8%)
Away for holiday 4 (19.0)
Admitted to hospital 3 (14.3%)
For other reasons (too busy) 2 (9.5%)
* One respondent moved to Australia and continued completing the questionnaires.BMC Cancer 2009, 9:277 http://www.biomedcentral.com/1471-2407/9/277
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time as being asked to participate in an observational
study which may increase the burden on the older
patients and may affect response rates and retention rates
in both studies. Unfortunately we did not have the infor-
mation on how often the patients who refused to partici-
pate were asked to participate in a clinical trial. However,
one patient who refused to participate told us that she was
participating in a clinical trial and thought the burden of
both studies would be too much. In addition, one physi-
cian asked that we not contact an eligible patient because
he wanted to enrol the patient in a clinical trial and
thought both studies would be too much. Nevertheless,
none of our dropouts during the study were participating
in a clinical trial. Future studies should take into account
the double study burden of participating in both an obser-
vational study and clinical trial.
The planning of interviews with participants undergoing
cancer treatment needed to be flexible as a significant
number of participants had to postpone and reschedule
interview appointments due to a variety of reasons. This is
in agreement with the study of Shipman et al [62] where
patients with advanced lung or colorectal cancer (n = 20)
were interviewed to determine their views about partici-
pating in serial questionnaires studies. These authors also
reported that the interview appointments were often post-
poned and patients reported that an interview duration of
30–45 minutes in length would be preferred with a pref-
erence for face-to-face interviews which is in agreement
with our findings [62]. It was also important for partici-
pants, as far as possible, to have the interviews done by the
same person and to offer home visits and transportation.
For each face-to-face data collection about half of the
interviews were conducted at home. Furthermore, partici-
pants in our study who were born outside Canada and
who were not native English or French speakers preferred
to have a family member present during the interviews in
case they might not understand the question. In most of
these cases, interviews were done in the oncology centre
while participants were with a family member waiting to
see their oncologist and this is partly the reason why some
interviews were postponed until the next appointment.
To our knowledge this is one of the first studies with older
newly-diagnosed cancer patients examining the recruit-
ment and retention strategies for an observational study
that begins prior to cancer treatment. A limitation of our
study is that we only recruited participants at one cancer
centre and the recruitment and retention process in other
hospitals may differ. Due to the small numbers of patients
Table 5: Feedback obtained from participants
Agreement with the statement "Interviews were 
too long"
Face-to-face interviews N = 84 (%) Telephone interviews
N = 84 (%)
Strongly disagree 37 (44.0%) 34 (40.5%)
Disagree 41 (48.8%) 45 (53.6%)
No opinion 1 (1.2%) 0
Agree 1 (1.2%) 2 (2.4%)
Strongly agree 4 (4.8%) 3 (3.6%)
Which questions were too difficult or unpleasant? Number of patients who reported this
Cognitive tests were too easy or irrelevant 6
Gait speed test, felt shy walking in clinic where other people can see the person walk 1
The interview was too easy 2
Most of questions are not relevant as patient did not feel sick, more suited for more sick patients 2
All questions were relevant 3
The questions were okay (not too strenuous) 3
Too much questions 2
The wide variety of questions makes it interesting 1
Which items/topics with regard to health and functional status are missing? Number of patients who reported this
Living situation (are you happy where you live?) 1
Perceptions of treatment 1
Number of patients who reported this
Social support/care received from family and friends 2
Loneliness 1
Which items/topics with regard to health and functional status are missing? Number of patients who reported this
Physical activity/hobbies (changes in type and amount of activities) 2
Nutritional problems including change in taste 1
Future (life after treatment) 2
Other comments or suggestions with regard to the conduct of this study Number of patients who reported this
I enjoyed participating in this study 30
Comments with regard to specific hospital services that are lacking 2BMC Cancer 2009, 9:277 http://www.biomedcentral.com/1471-2407/9/277
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who refused, statistical analyses to compare the character-
istics of the refusers to the participants were not possible.
Nevertheless, many of the lessons learned in our study
(same interviewer, having participants choose the place
and time of interview and identifying a proxy during the
informed consent procedure) are most likely applicable to
other sites when trying to recruit older newly-diagnosed
cancer patients. The feedback obtained shows that older
newly-diagnosed cancer patients are willing to participate
in observational studies while receiving cancer treatment.
There is a need to refine the recruitment and retention
strategies for conducting observational research with
older cancer patients.
Key points for recruitment and retention
￿ Be present in the oncology clinics so that the physi-
cian is reminded to verify eligibility of the patient, to
ask the patient permission to be contacted by a mem-
ber of the research team. If the patient agrees to be
contacted, the patient can briefly meet with you to
know who will be calling or you can explain the study
in person in the clinic.
￿ Provide all physicians involved in the patient recruit-
ment with all the materials plasticized in bright colors
to post in their exam rooms to remind them of the
inclusion and exclusion criteria.
￿ Adjust the recruitment strategies for all the depart-
ments involved if necessary and evaluate continu-
ously.
￿ During the informed consent procedure, ask consent
to be able to contact a proxy to locate the patient for
interviews as older cancer patients are often admitted
in several health care institutions during the course of
treatment.
￿ Be flexible when planning the interviews and offer
home visits and transportation to the interviews.
￿ Organize interviews so that involved family mem-
bers or friends can be present at the interviews.
￿ Adjust the materials/interviews to older persons with
visual and hearing impairment.
￿ Use the same interviewer as much as possible.
￿ Send reminder letters and questionnaires in
advance.
￿ Ask the patient consent to inform their treating phy-
sician of the results of the interview. Send a summary
of the interview to all the physicians within a week of
the interview which includes the list of important
findings on the different measurement tools used
including the established cut-offs, if available.
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